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Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian 
cancer risk 
ABSTRACT 
 
Rare and low frequency variants are not well covered in most germline genotyping arrays and are 
understudied in relation to epithelial ovarian cancer (EOC) risk. To address this gap, we used genotyping 
arrays targeting rarer protein-coding variation in 8,165 EOC cases and 11,619 controls from the international 
Ovarian Cancer Association Consortium (OCAC). Pooled association analyses were conducted at the variant 
and gene level for 98,543 variants directly genotyped through two exome genotyping projects. Only common 
variants that represent or are in strong linkage disequilibrium (LD) with previously-identified 
signals at established loci reached traditional thresholds for exome-wide significance (P<5.0x10
-7
). One of 
the most significant signals (Pall histologies=1.01x10
-13
;Pserous=3.54x10
-14
) occurred at 3q25.31 for rs62273959, 
a missense variant mapping to the LEKR1 gene that is in LD (r
2
=0.90) with a previously identified ‘best 
hit’ (rs7651446) mapping to an intron of TIPARP. Suggestive associations (5.0x10
-5
>P>=5.0 x10-
7
) were 
detected for rare and low-frequency variants at 16 novel loci. Four rare m i s s e n s e  variants were identified 
(ACTBL2 rs73757391 (5q11.2), BTD rs200337373 (3p25.1), K R T 1 3  r s 1 5 0 3 2 1 8 0 9  ( 1 7 q 2 1 . 2 )  
and MC2R rs104894658 (18p11.21)), but only MC2R rs104894668 had a large effect size (OR=9.66).  
Genes most strongly associated with EOC risk included ACTBL2 (PAML=3.23 x 10
-5
; PSKAT-o=9.23x10
-4
) 
and KRT13 (PAML=1.67 x 10
-4; PSKAT-o=1.07x10
-5), reaffirming variant-level analysis. In summary, this large 
study identified several rare and low-frequency variants and genes that may contribute to EOC susceptibility, 
albeit with possible small effects. Future studies that integrate epidemiology, sequencing, and functional 
assays are needed to further unravel the unexplained heritability and biology of this disease. 
INTRODUCTION 
 
         Epithelial ovarian cancer (EOC) has a strong heritable component, with an estimated three-fold increased 
risk among women with a first-degree relative having the disease (1). The excess familial risk that is not 
attributed to high penetrance mutations in genes such as BRCA1 and BRCA2 may be due to a combination of 
common and rare alleles that confer low- to moderate penetrance(2, 3). Genome-wide association studies 
(GWAS) of EOC t h a t  h a v e  b e e n  c o n d u c t e d  u s i n g  m o s t  o f  t h e  s a m p l e s  i n c l u d e d   
i n  t h e  c u r r e n t  i n v e s t i g a t i o n  have identified common variants at approximately 22 loci that 
collectively a c c o u n t  for 4% of the estimated heritability (4-13).  Few data exist regarding the contribution 
of rare (minor allele frequency (MAF) <0.5%) and low frequency (MAF 0.5-5%) protein-coding variants to 
EOC risk. This reflects the fact that protein- coding variants have not been targeted by conventional 
GWAS(14) despite prediction that their effects could be substantial(15) and imputation is known to be 
challenging for rare variants(16). 
Following GWAS arrays of the mid-2000s, exome-based arrays were developed in 2012. The 
Affymetrix Axiom ® Exome Genotyping Array and the Illumina HumanExome Beadchip each contain 
>245,000 putative functional coding variants and other categories of variants selected from 16 exome 
sequencing initiatives that included approximately 12,000 individuals of diverse ethnic backgrounds and a 
range of diseases(17) (Supplementary Table 1). Variants were included as ‘fixed’ content on the arrays 
if they occurred at least three times and were seen in two or more of the 16 studies (17). Here, we report 
the first large-scale genetic association study of uncommon exome-wide variants and EOC risk among nearly 
20,000 women (Supplementary Table 2). 
 
 
 
RESULTS 
 
Of the 98,299 polymorphic variants successfully genotyped as part of EOC case-control set 1 and set 
 
2 (7,308 cases and 10,773 controls; Supplementary Figure 1), most (68%) were rare (MAF < 0.5%), 
many (20%) were common (n=19,565, MAF >5%), and 12% (n=12,175) were low frequency (MAF between 
0.5% and 5%). The majority of these variants were non-synonymous (87%) with 81% missense, 1% nonsense, 
4% located in splice sites, and <1% resulting in a frame shift. 
 
 
 
Single variant associations 
 
The quantile-quantile (Q-Q) plot of the distribution of test statistics for the comparison of genotype 
frequencies in cases and controls showed slight inflation in the median test statistics of the likelihood ratio tests 
(λ=1.15; Supplementary Figure 2). This slight inflation may be explained by properties of the likelihood 
ratio test which make it sensitive to rare variants(18). No rare or low-frequency variants were statistically 
significantly associated with EOC risk (P<5.0x10-7); only common variants that represent or are in strong 
linkage disequilibrium (LD) with previously-identified signals at established loci (2q31.1, 3q25.31, 
8q24.21, 9p22.2, 17q12, 17q21.3, and 19p13.1) reached traditional thresholds for exome-wide significance 
(P<5.0x10
-7
) (Figures 1A and 1B, Supp l emen t a ry  Table 3).  B r i e f l y ,  the most statistically 
significant association was observed at 9p22.2 for a previously identified intronic variant near the BNC2 
(basonuclin2) gene(4), rs38114113, with an odds ratio (OR), 95% confidence interval (CI), and P-value of 
0.78 (0.75-0.82) (P=2.96 x10
-24
) and 0.75 (0.72-0.79) (P=3.32x10
-28
) among all histologies and serous 
histology, respectively. rs38114113 is correlated (r
2
=0.57-0.95) with two other detected SNPs (P=10-18) near 
BNC2. The full genome-wide set of summary association statistics are given in Supplementary Table 4. 
 The next most significant signal was at 3q25.31, with rs62273959 P=1.01x10-13 and P=3.54x10-14 in all 
 
histologies (OR=1.41) and serous only (OR=1.45) analyses. rs62273959 is a missense variant mapping to the 
LEKR1 (leucine, glutamate and lysine rich 1) gene which is in LD (r
2
=0.90) with a previously identified 
‘best hit’, rs7651446(12) that is located in an intron of TIPARP (TCDD-inducible poly(ADP- ribose) 
polymerase). Imputation of the region (see Supplementary Methods) identified rs78561123 (T>C) 
(P=2.97x10
-15
), a novel top-ranking variant that maps within 0.5kb of the 3’UTR for LINC00886 (long 
intergenic non-protein coding RNA 886) and is in strong LD with rs7651446 (r
2
=0.97) and rs62273959 
(r
2
=0.93) (Supplementary Figure 3A). The minor alleles of these three variants are located within the same 
haplotype associated with an increased risk among all histologies (OR (95% CI=1.41 (1.29-1.55), P=3.14x 
10
-13
). A fixed-effect meta-analysis of our study with an imputed dataset from the COGS genotyping initiative 
(19) also revealed stronger associations for variants located near TIPARP and LINC00886 (Supplementary 
Figure 3B).   The combined analysis of set 1 and set 2 also confirmed the existence of known common EOC 
susceptibility alleles or their proxies at 17q12, 8q24.21, 17q21.3, and 19p13.1 (P<5.0x10
-7
) (Supplementary 
Table 3). 
Associations for variants reaching a less stringent threshold (5.0x10
-5
>P>=5.0 x10
-7
) were detected 
among all histologies, serous histology, or endometrioid histology at 16 novel loci (1p36.33, 2p22.1, 3p25.1, 
3p14.2, 5q11.2, 6p22.1,  6p21.33, 6q25.2, 6p12.1, 8q21.13, 11q13.1, 15q12, 16q22.3, 17q.21.2, 18p11.21, 
and 22q11.2) (Table 1;Figures 2A and 2B). Of the novel variants that were identified, most were common 
and four were rare (MAFcontrols<0.003). The four rare missense variants (map to actin, beta-like 2, ACTBL2 
(5q11.2), biotinidase, BTD (3p25.1), keratin 13 type I, KRT13 (17q21.2), and melanocortin 2 receptor, MC2R 
(18p11.21). Visual inspection of cluster plots for all four rare variants underscored that the variant calling 
was good. Regional association plots for each of these rare variants reveal that they do not appear to 
be strongly correlated with other genotyped variants (Figure 3). The identified rare variants mapping to 
ACTBL2, BTD, and MC2R are predicted to be damaging per Polyphen-2 (Table 1). Due to low heterozygous 
genotype counts, it was not possible to estimate ORs for  variants at ACTBL2 and BTD. For rs150321809 
in KRT13 and rs104894658 in MC2R, the magnitudes of association were relatively high, with ORs of 
2.24 and 9.66, respectively, among all histologies.   Analysis of 883 invasive endometrioid cancers 
identified three c o m m o n  variants at P<5.0x10
-5 (Figure 2C; Table 1). We recently described the 
contribution of deleterious coding variants in seven putative EOC susceptibility genes (BRIP1, BARD1, 
PALB2, NBN, RAD51B, RAD51C, and RAD51D) to EOC risk (23, 24). The pooled exome dataset was used 
to examine associations for 68 variants that reside in these 7 genes. None of these variants reached levels of 
statistical significance (P<5.0x10
-5
) in overall, serous, or endometrioid specific analyses. The most significant 
rare variant in overall and serous analyses was BRIP1 rs4988345 (MAF=0.0047; P=0.022 and P=0.024, 
respectively), whereas PALB2 rs57605939  (MAF=0.0002) was the variant most significantly associated with 
endometrioid cancer risk (P=0.007). Similarly, we followed up on an exome sequencing study of 429 serous 
EOC cases and 557 controls by Kanchi et al.(25) in which rare truncation and missense variants were 
detected in known EOC susceptibility genes including BRCA1, BRCA2, CHEK2, and PALB2 and in genes not 
previously associated with EOC susceptibility  such as NF1 and CDKN2B. Only four of the rare truncation or 
missense variants they(25) identified were represented on either of the genotyping arrays utilized in the 
current investigation.  Applying a threshold of P<0.05 for these four variants (BRCA1_772, CLTC_1498, 
ERCC2_635, and ITK_448) only BRCA1_772 (p.Val772Ala; rs80357467, MAF= 0.00033) was associated 
with overall EOC susceptibility in our pooled analysis (OR (95%CI): =4.64 (1.22-17.7)), with P=0.014 
(serous OR=3.79, P=0.043). This variant is classified as non-pathogenic for the purposes of clinical 
management but may have a mild to moderate impact on risk(26). Thus, previously- detected rare variants 
were not strongly associated with EOC susceptibility in our larger dataset. 
We also evaluated association results for the 80,178 set 1 variants (N=5,431 case and 5,639 controls) 
that were not in the pooled dataset (Supplementary Figure 1). Results for the most statistically significant 
(P<5.0x10
-5
) set 1 variants are displayed in Supplementary Figures 4A-C and are summarized in 
Supplementary Table 5. Of six set 1 variants that were detected at the P<5.0x10
-5 threshold of statistical 
significance, the most statistically significant association was again with a common variant at a known locus 
rs62273902 (MAF=0.06) in the 5’ untranslated region of LEKR1 showing an increased EOC risk among 
all histologies (OR=1.42, P=1.91x10-
9
) and serous histology (OR=1.46, P=9.48x10-
10
) that is strongly 
correlated (r2=0.95) with rs62273959, a variant identified in the pooled analysis (Supplementary Table 3). 
Of the remaining five variants, one is rare and two have low frequencies.  Rare variant rs115783655 (T>C) 
(MAF=0.005) maps to an intron in IZUMO4 (IZUMO family member 4) and was associated with endometrioid 
cancer risk (P=3.32 x 10
-5
) while low frequency missense variants chr19:38572993 (A>G, MAF=0.02) in 
SIPA1L3 (signal-induced proliferation- associated 1 like 3) and rs148738146 (T>C, MAF=0.01) in 
PLA2G12A (phospholipase A2, group XIIA) were associated with decreased risks of EOC in all histologies 
and serous histology analyses (Supplementary Table 5). 
Eight of 9,600 indels assessed in set 1 only reached a threshold of P<9.0x10-4, and only one of these 
 
(rs147613544 at 8p21.3) is rare (MAF=0.0009) and was associated with a decreased risk for EOC (OR =0.16, 
P=5.0x10
-4
). Set 1 also assessed 146 variants in the mitochondrial genome; only one rare (MAF=0.003) non- 
synonymous variant c.6480G>A (p.Val193Ile) located within cytochrome c oxidase subunit 1 (COI) was 
strongly associated with decreased EOC susceptibility among all histologies (OR=0.54, P=0.0009) and serous 
histology (OR=0.24, P=0.0008). G6480A has been associated with an increased risk for prostate cancer in 
African Americans (27). 
 
 
 
Gene-level associations 
 
In combined analysis of Affymetrix- and Illumina-based data, thirteen genes had P-values less than 
5x10-4 for an association with EOC susceptibility overall based on the RAML test(28) (Figure 4). 
Consistency was observed when comparing gene-level findings from RAML to those based on the SKAT-O(29) 
tests (Table 2). The genes that were most strongly associated with EOC risk using RAML included actin, 
beta-like 2, ACTBL2 (PAML=3.23 x 10
-5
; PSKAT-o=9.23x10
-4
) and keratin 13, KRT13 (PAML=1.67 x 10
-4; 
PSKAT-o=1.07x10
-5); these genes contained individual variants ( rs73757391 and rs150321809) associated with 
EOC risk (5.0x10-5>P>=5.0x10-7) highlighted in Table 1.  Details regarding the set of rare variants that 
contributed to gene-level findings for ACTBL2 and KRT13 are summarized in Supplementary Table 6.   
ACTBL2  and  KRT  were also  statistically  significant  in  the  serous- only  analysis  after  multiple correction 
testing using a FDR threshold of 15%(30). Of the genes featured in Table 2, MC2R a l s o  contained 
individual r a r e  variants associated with EOC risk (5.0x10
-5
>P>=5.0x10
-7
) (Table 1). W h e n  
c o m p a r i n g  primary high-grade serous EOC tumors and normal fallopian tube tissues in the TCGA 
dataset, two of the aforementioned genes were differentially expressed: KRT13 was overexpressed in tumor 
versus normal tissue (p=0.034) while MC2R was under-expressed (p=0.004), though neither finding was 
significant after adjustment for multiple comparisons. 
               Gene-level results for the 15,042 genes encompassed by set 1 only variants d i d  n o t  
h i g h l i g h t  ACTBL2 , KRT13, or MC2R.  Rather,  leukocyte receptor tyrosine kinase (LTK) (P=2.22x10
-5
), 
ATPase NA+/K+ transporting alpha 3 polypeptide (ATP1A3) (P=8.33x10-5), and son of sevenless homolog 
2 (SOS2) (P=4.55x10
-5
) were identified as the most strongly associated genes among all histologies, serous 
histology, and endometrioid histology, respectively (Supplementary Table 7; Supplementary Figure 5).    
Collectively, all genotyped uncommon variants (MAF<0.05%) explained 4.7% of the phenotypic variation in 
our subjects (54).  Only 2% (.11/4.7) of this variation c a n  b e  a t t r i b u t e d  t o variants with P< 5.0x10
-5 
(Supplemental Methods).  
 
 
DISCUSSION 
 
We report an EOC risk association analysis of 98,299 variants enriched for rare and low frequency 
protein-coding changes among nearly 20,000 women using commercially available genotyping arrays. 
Assuming a disease prevalence of 1.4%, our sample size was adequately powered (~89%) to detect 
associations with low frequency variants i n c l u d e d  o n  t h e  e x o m e  a r r a y s  and moderate effect sizes 
(OR>1.35) should they exist, but we did not identify any novel uncommon variants at exome-wide levels of 
statistical significance (P<5.0x 10
-7
). Instead, association with common variants (MAF>5%) at known EOC 
loci (2q31.1, 3q25.31, 8q24.21, 9p22.2, 17q12, 17q21.3, and 19p13.1)(4-6, 10, 19) were identified; most of 
these variants were (or were in strong LD with) the previously reported top-ranking variant at the locus. 
Importantly, sixteen novel loci with low-frequency or rare variants at P<5.0 x10-5 were detected. Four rare 
variants were identified (ACTBL2 rs73757391 (5q11.2), BTD rs200337373 (3p25.1), KRT13 rs150321809 
(17q21.2), and MC2R rs104894658 (18p11.21)), and gene-level analyses revealed statistically significant 
associations with variation in three of these genes. These results are consistent with the known landscape of 
common genetic variation in EOC risk and the utility of multi-marker testing for rare variation. They suggest 
that the effect sizes of rare coding variants with MAF that  are in  the  range included on  the exome 
arrays  may be less than 1.35, requiring larger sample sizes and the use of a family-based approach for 
their discovery. Indeed, recent simulation studies suggest that sample sizes of 60,000-100,000 will be needed 
to detect small effect sizes for rare variants (MAF<0.5%) when using exome genotyping arrays(31). 
Among the four rare variants that were identified, rs73757391, rs200337373, and rs104894658 are 
non-synonymous and predicted to be damaging. Moreover, according to the ClinVar database(26), BTD 
rs200337373 (G>A) and MC2R rs104894658 (C>A) are reported to be pathogenic for biotinidase deficiency 
and  adrenocorticotropic  hormone  (ACTH)  resistance  observed  in  familial  glucocorticoid  deficiency(32), 
respectively. Importantly, gene-level analysis using different methods highlighted ACTBL2, KRT13, and MC2R 
as being strongly associated with EOC risk overall and serous disease. Whereas ACTBL2 is a cytoskeletal 
protein abundantly expressed in vascular smooth muscle cells(33) that has no reported link to cancer, BTD 
(biotinidase) is a putative biomarker of breast cancer(34), papillary thyroid cancer aggressiveness(35), and 
lymph node involvement in patients with early stage cervical cancer(36). In vivo a deficiency of biotinidase 
affects the expression of central-carbon metabolism genes(37), a pathway important in the development and 
progression of EOC(38, 39). KRT13 encodes a cytoskeletal protein downregulated in an estrogen receptor 
(ER) positive ovarian cancer cell line(40) and contributes to breast cancer growth and metastasis through its 
interaction with estradiol and the selective estrogen receptor modulators, tamoxifen and raloxifene(41). MCR2 
belongs to a family of melanocortin receptors involved in the regulation of food intake, inflammation, 
skin pigmentation, sexual function, and steroidogenesis, in part by binding to adrenocorticotropic hormone 
(ACTH)(42, 43). ACTH-producing ovarian tumors have been reported (44-46), but this has been in the context 
of Cushing’s syndrome and non-epithelial ovarian cancers. Taken together, there is biological plausibility to 
explain some but not all of the current association results. 
Independent replication of novel rare variant associations is important but challenging because of the 
lack of appropriate replication panels. The large COGS EOC meta-GWAS(19) with imputation to Phase I 1000 
genome project data was completed after the onset of this study. As a form of replication, we attempted to 
interrogate this dataset(19) for the most strongly associated novel rare variants. Unfortunately, rare variants 
and their proxies were not represented in the imputed dataset, precluding the possibility of replication and the 
opportunity  to  evaluate  associations  between  germline  genotype  and  gene  expression  via  expression 
quantitative trait locus analysis. Furthermore, our attempt to replicate associations with rare variants identified 
in studies of EOC that were much smaller than ours (23-25) did not yield statistically significant findings. 
The limited evidence for novel rare or low frequency coding variants at exome-wide levels of 
significance is consistent with studies of other complex diseases (myocardial infarction(51), Alzheimer’s 
disease(52), and insulin processing and secretion(53)) that used these exome genotyping arrays. Published 
investigations of exome genotyping array data are limited for other cancers, precluding comparison of findings 
across cancer types. The limited evidence for rare or low-frequency coding variants may be expected when 
using rare variant chips for cohorts or diseases for which they were not originally designed. Integration 
of sequencing data in very large sample sizes may be an effective strategy for discovering additional rare 
EOC alleles in the future since the arrays do not provide complete coverage of all functional variants at each 
locus and the accuracy of imputation for rare variants is suboptimal. Even with such limitations, the current 
study suggests that rare coding variants with large effects m a y  exist, although they did not account for 
a significant fraction of EOC heritability within our data. In total, rare variants accounted for 4.7% of the 
phenotypic variation in our subjects (54) with only 2% (.11/4.7) of this variation from variants with P< 
5.0x10
-5 (Supplemental Methods). The remaining 98% of variance attributable to rare variants in this study 
could be due to small effect sizes that did not reach statistical significance. In the absence of opportunities to 
significantly increase sample sizes, future studies should rely on closer integration of epidemiology and 
laboratory assays of functional effects to further unravel the etiology of this disease. 
 
 
 
MATERIALS AND METHODS 
 
Study Population and Genotyping 
 
Study participants came from 27 independent studies in the international Ovarian Cancer Consortium 
(OCAC)(55) (Supplementary Table 2 ). In brief, cases were women with pathologically-confirmed primary 
invasive EOC, fallopian tube cancer, or peritoneal cancer, and controls were women without EOC, with at least 
one ovary intact, and for most studies were frequency-matched to controls on age group and self-reported 
race. Specimens and data were collected according to protocols approved by local institutional review and 
ethics boards. Germline DNA samples from 19 studies (Set 1, 7,060 EOC cases and 6,712 controls) were 
genotyped on the Affymetrix Axiom Exome Genotyping Array at the Affymetrix Service Lab (Santa Clara, 
CA, USA), and those from eight studies (Set 2, 2,109 cases, 5,646 controls) were genotyped on the 
Illumina HumanExome Beadchip at the Strangeways Research Lab (University of Cambridge, United 
Kingdom). 
 
 
 
Genotyping Quality Control (QC) 
 
Set 1 genotyping was performed in batches grouped according to sample type (genomic  blood, genomic 
saliva, whole genome-amplified (WGA) blood, WGA saliva). Affymetrix Genotyping Console™ Software 
was used for automated allele calling for each batch, followed by initial sample and variant QC performed  
per  protocol  (http://media.affymetrix.com/support/downloads/manuals/axiom). Since significant batch effects 
were observed, intensity data from the genomic samples were combined into a single batch to enable the 
automated clustering algorithm to more accurately detect rare variants(56). WGA samples were not recalled as 
one batch because of known chemistry differences between the component batches (personal 
communication, Affymetrix, Inc). Four hundred thirty-seven samples were genotyped in duplicate and were 
identified with 99.8% concordance. As shown in Supplementary Figure 1, of 13,772 unique samples that 
were genotyped, 454 (3.3%) were excluded because they failed Affymetrix QC metrics (<97% call rate or dish 
QC < 0.82) and an additional 545 samples were excluded because of ambiguous gender, replicate 
discordance, sample relatedness, or failure to meet eligibility criteria for the primary analysis. Of 302,461 
variants on the Affymetrix array, 123,934 variants (41%) were excluded for QC reasons which mostly included 
failed Affymetrix cluster QC, monomorphism, deviation from Hardy Weinberg Equilibrium (HWE) P<10-
7 in controls, or discordant B allele frequencies between the genomic and WGA samples. A total of 
12,773 samples (6,288 case and 6,485 controls) and 178,527 variants genotyped on the Affymetrix platform 
passed QC steps. HapMap DNA samples for European (CEU, n=60), African (YRI, n=53) and Asian 
(JPT+CHB, n=88) populations were also genotyped, and the program LAMP(57) was used to estimate 
intercontinental ancestry based on the HapMap (release no. 23)  genotype frequency  data for  the European, 
Asian, and African populations. Subjects with greater than 90% European ancestry were included in analyses 
(5,431 cases, 5,639 controls) (Supplementary Figure 1). Genotype data for set 1 are being released into 
dbGAP per NIH guidelines. 
Set 2 genotyping was performed for 7,612 samples, and genotype calling was carried out according 
to Best Practice Guidelines(56) using the GenCall(58) module in Illumina's Genome Studio with a default 
GenCall threshold of 0.15. After initial sample QC, zCall(59) was calibrated to a z-value of 8 and run for 
all variants. One hundred and forty-three samples were genotyped in duplicate and identified with 92% 
concordance. Initial sample QC excluded 248 samples with low call rates (<70%). After zCall calibration 
and variant recall, we further excluded 221 (3%) samples for reasons including <99% call rate, high or 
low heterozygosity at a significance level of 10
-16
, ambiguous gender, relatedness, or genotypes discordant 
with prior genotypes from the international Collaborative Oncological Gene-Environment Study (iCOGS) 
genotyping array(19). Genotyping also included HapMap DNA samples (CEU, n=95; YRI, n=82; JPT+CHB, 
n=93), and ancestry was assessed using the IBS matrix for all samples combined with HapMap samples over 
the uncorrelated variants. Using this multi-dimensional scaling  on a weighted identity by state matrix, 
non-European samples at a distance of greater than 10% were excluded (n=97) (Supplementary Figure 
1). Of the 247,870 markers on the Illumina array, we excluded 94,231 variants (38%) for reasons 
including call rate <95%, poor cluster separation, duplicate probes, monomorphism, and deviation from 
HWE (Supplementary Figure 1). We tested for HWE using a Robertson and Hill test statistic stratified by 
study(60) and an exact test. Variants that failed both tests were excluded using exclusion thresholds of p-
values < 10-
12 and 10
-6 for cases and controls, respectively. After all exclusions there were 7,046 
European ancestry samples (1,878 cases and 5,168 controls) and 153,639 variants genotyped on the 
Illumina platform (Supplementary Figure 1). Thirty-five samples were genotyped in common as part of set 
1 and set 2; the genotype concordance rate was 99.66%. 
Thus, a combined total of 18,081 unique subjects of European ancestry (7,308 cases, 10,773 controls) 
were genotyped and passed sample QC. Of the 18,081 subjects, 5,138 (997 cases and 4,141 controls) were 
not previously genotyped as part of a previously described EOC GWAS or post-GWAS initiative (4, 5, 19). 
Of the variants passing QC for each set, 98,543 were present on both platforms and available for pooled analysis 
(Supplementary Figure 1), excluding non-autosomal variants (n=1,983) and those with discordant B allele 
frequencies between the two sets (n=32). On this combined dataset, we carried out principal components 
analysis (PCA) to examine the sub-European population structure using a linkage-disequilibrium-pruned set of 
27,335 autosomal markers with MAF>1% and HWE P value > 10
-7
. We inspected the first 10 principal 
components (PC) for evidence of population stratification in the pooled samples. 
 
Single Variant Analysis 
 
 
Each variant was tested for a per allele association with EOC risk using a likelihood ratio  test 
comparing the deviance (-2 × log-likelihood) of two generalized linear models with and without the variant. 
Models were adjusted for set (1 versus 2) and the first five PCs representing sub-European ancestry. When 
adjusted for study alone, there was an inflation of the test statistics (λ = 1.20, λ1000 = 1.024) which was 
reduced to λ = 1.15, (λ1000 = 1.018) after adjustment for five principal components (61). Visual inspection 
of intensity cluster plots resulted in the elimination of 244 variants with poor differentiation between 
heterozygote and homozygote calls (Supplementary Figure 1). Subgroup analysis was conducted for 
the two most common histologic subtypes: serous and endometrioid. Using a stringent Bonferroni 
correction for 98,299 tests, we considered variants with P<5.0x10-7 to be statistically significant. Because of 
the greater number of variants and samples in set 1, we also explored associations for 80,178 variants from 
set 1 that passed visual cluster inspection and were not included in the Illumina array; for these analyses, we 
adjusted for the first 3 PCs. 
 
 
 
Gene-level Analysis 
 
Given the emphasis of each array on exomic coverage(62), gene-level tests were also conducted, 
mapping variants within 50 kb to genes based on Genome Build 37 coordinates and gene annotation that was 
curated by Affymetrix from UCSC Genome Bowser data tables. In total, 71,044 variants mapped to 15,118 
genes of which 12,123 genes contained more than one variant and were evaluated for the pooled gene-level 
analysis. Two methods were used for gene-level analyses because of some similarity in assumptions and the 
ability to include covariates in the underlying regression model: a) the rare admixture maximum likelihood 
test (RAML)(63), which makes no assumptions about the proportion of variants that are associated with 
the phenotype of interest or the magnitude and direction of their effect and b) the Sequence Kernel 
Association Test -Optimal unified test (SKAT-O)(64), a score-based variance-component test that is 
powerful when the direction of association for variants can be increased or decreased. Both methods 
considered only rare variants (MAF <1%) and were not weighted based on MAF. False discovery rate (FDR) 
is used to adjust for multiple comparisons and FDR of 15% is used to declare significance. Similarly, we also 
conducted gene-level analysis with the larger set of variants in set 1 which totaled 15,042 genes and 128,992 
variants. For genes that were most strongly associated with EOC susceptibility, we mined publicly available 
gene expression data from the Cancer Genome Atlas Project (TCGA)(65) and compared gene expression 
between 568 high-grade serous ovarian tumors and 10 normal fallopian tube tissues according to previously 
described methods(9). 
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LEGENDS TO FIGURES 
  
Figure 1. Manhattan plot of association for 98,299 SNPs from a pooled analysis of Affymetrix and Illumina 
exome genotyping arrays.  Plots show the strength of association versus chromosomal position for 
(A) all invasive EOC risk and (B) serous invasive EOC risk. The red line represents exome-wide significance 
(5.0x10-7). Exome-wide significant variants are annotated for the gene in which they are located. Known 
variants previously reported to have the strongest association signal are indicated by a black diamond. 
 
 
 
Figure 2. Manhattan plot of association for sub-exome-wide (P > 5.0x10-7) variants from a pooled 
analysis of Affymetrix and Illumina exome genotyping arrays. SNPs with P < 5.0x10-7 were filtered out and 
the strength of genetic association versus chromosomal position was plotted for the remaining 98,287 SNPs  for 
the risk of (A) all invasive EOCs, (B) serous invasive EOCs, and (C) endometrioid invasive EOCs.  Known 
variants previously reported to have the strongest association signal are indicated by a black diamond. Sub- 
exome-wide significant SNPs (P < 5.0x10-5) are annotated for the gene in which they are located. 
 
 
 
Figure 3. Regional association plots for rare variants associated with EOC susceptibility. 
 
A)  BTD rs200337373 (3p25.1), B) ACTBL2 rs73757391 (5q11.2), C) KRT13 rs150321809, 
 
(17q21.2), and D) MC2R rs104894658 (18p11.21)). Linkage disequilibrium (LD, r2) between the strongest 
signal (noted by a purple diamond) and other variants is indicated by the color scheme. 
 
 
 
Figure 4. Gene-level association of rare variants (MAF<1%) using the Rare Admixture Maximum 
Likelihood (RAML) association test. Results of association with all invasive EOC risk are shown for 15,118 
genes, adjusting for study and first 5 PCs. Genes with P < 5.0x10-4 are annotated. 
 
 
Supplemental Figure 1. Sample and variant quality control and data pooling flowchart. 
 
 
 
 
Supplemental Figure 2. Quantile-Quantile plot of distribution of test statistics for 98,299 SNPs in primary 
pooled analysis. Plot shows the observed test statistics from the likelihood ratio test versus the 
expected test statistic. The ratio of the empirically observed median test statistic to the expected median (λ) is 1.13. 
 
 
 
Supplemental Figure 3. Regional association plot for variants directly genotyped or imputed at the 3q25 
susceptibility locus.  Directly genotyped variant in LEKR1, rs62273959, is strongly correlated (0.93>r2>0.96) 
with previously reported intronic variant near TIPARP (rs7651446) and newly imputed variant, rs78561123,which 
that maps within 0.5kb of the 3’UTR for LINC00886. 
 
 
 
Supplemental Figure 4. Manhattan plot of association for 80,178 SNPs from Set 1 only analysis (Affymetrix). 
Plots show association between genotype and risk of (A) all invasive EOC, (B) serous EOC, and 
(C) endometrioid EOC. The red line represents exome-wide significance (5.0x10-7) and exome-wide or sub- 
exome-wide significant SNPs (P < 5.0x10-5) are annotated for the gene in which they are located. 
 
 
 
Supplemental Figure 5. Gene-level association of rare variants (MAF<1%) using RAML association test for 
Set 1 only analysis (Affymetrix). Results of association with all invasive EOC risk are shown for 15,042 genes, 
adjusting for the first 3 PCs. Genes with P < 5.0x10-4 are annotated.  
  
       Table 1.  Variants at Novel Loci Associated with Epithelial Ovarian Cancer Susceptibility with 5.0x10-5>P>=5.0 x10-7 
       
All Invasive 
(7308 cases, 10773 controls) 
Serous 
(5955 cases, 10773 controls) 
Endometrioid 
(883 cases, 10773 controls) 
Regiona 
rsID 
(major>minor allele) 
Position 
(hg19) 
Nearest 
Gene(s) 
Function 
(Polyphen 
score/ 
prediction) 
Case 
MAF 
Control 
MAF 
OR 
(95% CI)b 
P value 
OR 
(95% CI)b 
P value 
OR 
(95% CI)b 
P value 
1p36.33 rs138031468 (G>T) 977028 AGRN 
Missense: 
A375S 0.005 0.007 0.79 (0.60-1.03) 8.34E-02 0.91 (0.7-1.2) 5.20E-01 0.08 (0.01-0.56) 3.80E-05 
2p22.1 rs61757604 (C>T) 39095403 DHX57 
Missense: 
G49S 
(0.318/B) 
0.02 0.02 0.82 (0.68-0.99) 3.55E-02 0.92 (0.75-1.11) 3.69E-01 0.26 (0.12-0.56) 2.21E-05 
3p25.1 rs200337373 (G>A) 15686027 BTD 
Missense: 
D222N 
(0.999/D) 
0.001 0 NEc 8.61E-06 NEc 1.75E-05 NEc 4.74E-02 
3p14.2 rs4679621 (C>T) 59324733 
C3orf67 
(289kb) 
FHIT 
(410kb) 
Intergenic 0.47 0.44 1.1 (1.05-1.14) 4.19E-05 1.1 (1.05-1.15) 3.95E-05 1.03 (0.93-1.14) 5.82E-01 
5q11.2 rs381852 (G>A) 54459961 
GPX8 
CDC20B 
Missense: 
K182R (0/B), 
Intron 
0.21 0.18 1.13 (1.07-1.2) 1.63E-05 1.14 (1.08-1.21) 9.07E-06 1.05 (0.92-1.2) 4.72E-01 
5q11.2 rs73757391 (C>T) 56778213 ACTBL2 
Missense: 
E108K 
(1.0/D) 
0.001 0 NEc 6.37E-06 NEc 5.15E-06 NEc 4.24E-02 
6p22.1 rs114979098 (C>T) 29785235 
HLA-G 
(10kb) 
Intergenic  0.42 0.41 1.11 (1.05-1.18) 4.82E-04 1.08 (1.02-1.15) 1.15E-02 1.37 (1.19-1.56) 5.15E-06 
6p21.33 rs149771958 (C>T) 31079994 C6orf15 
Missense: 
G48R 
(0.895/PD) 
0.07 0.08 0.84 (0.77-0.91) 4.24E-05 0.84 (0.77-0.92) 1.25E-04 0.86 (0.71-1.03) 1.01E-01 
 rs116682468 (C>T) 31112484 CCHCR1 
Missense: 
R627Q 
(1.0/D) 
0.07 0.07 0.83 (0.76-0.91) 3.90E-05 0.84 (0.77-0.92) 2.86E-04 0.82 (0.68-1) 4.55E-02 
 rs116151586 (T>C) 31118019 CCHCR1 Intron 0.32 0.32 0.88 (0.83-0.94) 4.60E-05 0.88 (0.83-0.94) 9.03E-05 0.84 (0.73-0.97) 1.39E-02 
 rs114470046 (C>A) 31125257 CCHCR1 
Nonsense: 
E41Stop 0.07 0.07 0.83 (0.76-0.91) 3.61E-05 0.84 (0.77-0.92) 2.75E-04 0.82 (0.67-1) 4.31E-02 
 rs115538919 (C>T) 31129707 TCF19 
Missense: 
P241L 
(0.906/PD) 
0.07 0.07 0.83 (0.76-0.91) 3.76E-05 0.84 (0.77-0.93) 3.09E-04 0.82 (0.68-1) 4.49E-02 
6p21.33 rs113935384 (G>A) 31231989 
HCG27 
(60kb) 
HLA-C 
(4.5kb) 
Intergenic 0.36 0.36 0.89 (0.84-0.94) 3.66E-05 0.89 (0.84-0.94) 1.09E-04 0.9 (0.79-1.02) 9.54E-02 
6p12.1 rs2297980 (A>G) 54173413 TINAG 
Missense: 
Q22R (0/B) 0.09 0.11 0.84 (0.78-0.9) 1.90E-06 0.83 (0.77-0.9) 2.25E-06 0.91 (0.76-1.07) 2.47E-01 
6q25.2 rs199761238 (T>C) 152652052 SYNE1 
Missense: 
N4590D 
(0.818/PD) 
0 0.001 0.15 (0.03-0.63) 1.06E-03 NEc 2.78E-05 1.33 (0.29-6.08) 7.22E-01 
11q13.1 rs145514333 (C>T) 64527189 PYGM 
Missense: 
R61H (1.0/D) 0.004 0.0001 3.18 (1.69-6.01) 1.49E-04 3.59 (1.91-6.77) 2.67E-05 0.84 (0.19-3.77) 8.18E-01 
15q12 rs147432497 (G>A) 25940059 ATP10A 
Missense: 
R999C 
(1.0/D) 
0 0.001 0.16 (0.04-0.67) 1.61E-03 NEc 4.13E-05 NEc 1.31E-01 
16q22.3 rs147445846 (G>C) 72992910 ZFHX3 
Missense: 
L379V 
(0.979/D) 
0.001 0.002 0.37 (0.22-0.62) 4.86E-05 0.34 (0.19-0.61) 7.01E-05 0.42 (0.13-1.34) 9.42E-02 
17q21.2 rs150321809 (C>T) 39657599 KRT13 
Missense: 
R429H 0.003 0.001 2.24 (1.52-3.31) 3.20E-05 2.45 (1.65-3.65) 6.49E-06 1.03 (0.4-2.67) 9.48E-01 
   
(0.266/B) 
18p11.21 rs104894658 (C>A) 13885297 MC2R 
Missense: 
S74I (1.0/D) 0.002 0.0003 
9.66 (2.73-
34.24) 
3.66E-05 10.15 (2.86-35.99) 2.76E-05 NEc 5.78E-02 
22q11.2 rs141200301 (C>T) 24123521 MMP11 
Missense: 
R334C 
(1.0/D) 
0.001 0 NEc 7.49E-05 NEc 3.91E-05 NA NA 
 Gene Information  Rare Admixture Maximum Likelihood (RAML) test1  Sequence Kernel Association Test (SKAT)1 
 
All Invasive Serous Endometrioid All Invasive Serous Endometrioid 
  N SNPs             
Gene Region (total/rare) P-value
2
 FDR P-value
2
 FDR P-value
2
 FDR P-value
2
 FDR P-value
2
 FDR P-value
2
 FDR 
 
Table 2: Genes most strongly associated with epithelial ovarian cancer risk, with P<5.0x10
-4 
by RAML 
 
 
 
 
      1Both the RAML and SKAT methods were limited to rare variants (MAF<1%).  No weighting by minor allele frequency was used in either method. 
2Analyses are adjusted for site and the first five principal components representing European ancestry. 
 
 
 
 
 
 
 
 
 
 
 
 
ACTBL2 5q11.2 6/6 3.23E-05 0.38 2.00E-05 0.15 2.99E-01 1 9.23E-04 0.56 1.50E-03 0.46 2.60E-01 0.98 
KRT13 17q21.2 7/7 1.67E-04 0.38 2.94E-05 0.15 2.65E-01 1 2.04E-05 0.15 5.24E-06 0.08 3.62E-01 0.98 
CLCNKA 1p36.13 3/3 2.00E-04 0.38 8.33E-05 0.25 5.60E-01 1 2.98E-04 0.48 6.08E-05 0.14 5.61E-01 0.98 
MYO19 17q12 14/11 2.00E-04 0.38 7.50E-04 0.37 1.84E-02 1 5.41E-03 0.64 9.30E-03 0.66 1.76E-02 0.74 
TNFSF15 9q32 8/3 2.20E-04 0.38 5.56E-05 0.21 2.56E-01 1 2.79E-04 0.48 4.39E-05 0.14 2.62E-01 0.98 
TRIB1 8q24.13 4/2 2.80E-04 0.38 3.67E-04 0.29 7.76E-01 1 4.90E-04 0.51 3.09E-04 0.26 7.25E-01 0.99 
MC2R 18p11.21 6/6 3.25E-04 0.38 2.00E-04 0.29 9.62E-02 1 1.32E-01 0.91 2.01E-01 0.93 8.26E-02 0.98 
LIG3 17q12 7/6 3.33E-04 0.38 1.70E-03 0.46 3.59E-02 1 4.91E-03 0.64 9.80E-03 0.66 4.62E-03 0.55 
CAMSAP3 19p13.2 4/3 3.67E-04 0.38 2.40E-04 0.29 3.54E-01 1 1.10E-04 0.37 6.76E-05 0.14 4.20E-01 0.98 
GSDMB 17q21.1 15/7 3.67E-04 0.38 4.33E-04 0.31 5.41E-01 1 2.78E-01 0.95 2.47E-01 0.93 2.49E-01 0.98 
KIAA1586 6p12.1 3/2 4.00E-04 0.38 3.33E-04 0.29 1.80E-01 1 4.70E-04 0.51 2.00E-04 0.26 1.53E-01 0.98 
SPTBN1 2p16.2 9/8 4.00E-04 0.38 2.10E-03 0.48 2.06E-01 1 1.16E-05 0.15 2.20E-04 0.26 3.88E-02 0.97 
STPG1 1p36.11 9/3 4.50E-04 0.40 7.50E-04 0.37 2.21E-01 1 4.50E-01 0.95 1.71E-01 0.92 1.84E-01 0.98 
GPATCH2 1q41 8/7 5.00E-04 0.42 3.67E-04 0.29 7.06E-01 1 3.26E-02 0.81 5.37E-02 0.84 1.00E+00 1.00 
CCDC136 7q33 12/11 5.33E-04 0.42 1.43E-04 0.26 7.47E-01 1 1.07E-02 0.75 8.68E-03 0.66 7.53E-01 0.99 
WDR59 16q23.1 10/8 1.00E-03 0.50 3.67E-04 0.29 2.58E-01 1 2.81E-03 0.61 2.67E-03 0.55 4.51E-01 0.98 
NEXN 1p31.1 3/3 1.00E-03 0.50 3.67E-04 0.29 1.91E-01 1 5.46E-03 0.64 3.64E-03 0.61 4.53E-01 0.98 
MMP11 22q11.23 5/4 1.20E-03 0.50 4.33E-04 0.31 2.98E-01 1 2.69E-01 0.95 4.25E-02 0.83 1.87E-01 0.98 
BCL9L 
 
PYGM 
11q23.3 
11q12- 
q13.2 
2/2 
 
11/11 
1.30E-03 
 
3.10E-03 
0.50 
 
0.66 
1.57E-04 
 
3.33E-04 
0.26 
 
0.29 
4.52E-01 
 
3.52E-01 
1 
 
1 
1.31E-03 
 
1.56E-01 
0.57 
 
0.92 
1.58E-04 
 
5.24E-02 
0.26 
 
0.83 
4.99E-01 
 
3.13E-01 
0.98 
 
0.98 
ATMIN 16q23.2 7/6 5.06E-02 0.94 3.27E-01 1 3.67E-04 1 1.23E-01 0.91 5.30E-01 0.94 9.09E-04 0.30 
SOS2 14q21 9/9 1.30E-01 0.99 3.71E-01 1 6.88E-05 1 8.85E-02 0.89 1.83E-01 0.92 6.34E-02 0.98 
OR7G1 19p13.2 9/3 1.97E-01 1.00 3.85E-01 1 2.40E-04 1 9.47E-02 0.90 3.00E-01 0.94 4.23E-04 0.23 
PRR5 22q13 5/4 3.71E-01 1.00 6.75E-01 1 3.67E-04 1 4.08E-01 0.95 8.36E-01 0.94 7.86E-02 0.98 
